• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

    Simply Wall St·08/16/2026 01:26:38
    Listen to the news
    • In August 2026, Cellebrite DI Ltd. reported half-year 2026 results, lowered its full-year revenue outlook to US$555 million–US$561 million with 17%–18% annual growth, and announced a planned CEO transition in which Shiven Ramji succeeded Thomas E. Hogan and joined the board.
    • These moves, combined with softer profitability and delayed large government contracts, have prompted investor scrutiny over execution, disclosure practices, and the pace of converting AI and cloud investments into more predictable recurring revenue.
    • Against this backdrop, we'll examine how the lowered 2026 revenue guidance reshapes Cellebrite DI's existing investment narrative built around federal AI and cloud demand.

    Uncover the next big thing with 18 elite penny stocks that balance risk and reward.

    Cellebrite DI Investment Narrative Recap

    To own Cellebrite DI, you have to believe its digital investigation platform and AI tools can turn complex, long sales cycles into growing, recurring revenue, especially with government customers. The latest guidance cut and delayed federal deals directly pressure that near term catalyst, while also amplifying the core risk around customer concentration and procurement bottlenecks, rather than introducing a new one.

    The most relevant announcement here is the lowered 2026 revenue outlook to US$555 million to US$561 million, alongside softer profitability. That reset underlines how much the story now hinges on the timing and reliability of large Inseyets and federal contracts, and whether Cellebrite’s AI and cloud portfolio can support more predictable ARR growth instead of lumpy, approval dependent wins.

    But beneath the product story, there is a less visible risk that investors should be aware of if federal contract delays and legal scrutiny around guidance...

    Read the full narrative on Cellebrite DI (it's free!)

    Cellebrite DI's narrative projects $787.4 million revenue and $122.0 million earnings by 2029. This requires 15.3% yearly revenue growth and a $63.8 million earnings increase from $58.2 million today.

    Uncover how Cellebrite DI's forecasts yield a $15.36 fair value, a 38% upside to its current price.

    Exploring Other Perspectives

    CLBT 1-Year Stock Price Chart
    CLBT 1-Year Stock Price Chart

    Before this setback, the most optimistic analysts were assuming revenue could reach about US$735 million and earnings US$207 million by 2028, so compared with the current guidance reset and federal exposure concerns, you can see how different your view of Cellebrite’s risk and reward might be and why it is worth weighing several perspectives.

    Explore 5 other fair value estimates on Cellebrite DI - why the stock might be worth as much as 98% more than the current price!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Searching For A Fresh Perspective?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.